The Pro10™ cell line is a new technology that enhances the efficiency and scalability of recombinant adeno-associated virus (rAAV) production for gene therapy manufacturing. This proprietary mammalian suspension technology is designed to address the challenges associated with large-scale manufacturing in AAV gene therapies. The cells have been fully characterized and licensed for gene therapy development by various biopharmaceutical companies.
Viralgen utilizes the Pro10™ cells as the core of a reliable and scalable rAAV vector manufacturing process. These cells have been optimized for rAAV production and can be scaled up to 2000L, showcasing consistent and reproducible cell growth rates. They have demonstrated similar productivity levels in both small and large-scale bioreactors and are capable of producing various AAV serotypes.
The Pro10™ cells play a critical role in Viralgen’s platform process for manufacturing AAV vectors, significantly contributing to the production of innovative gene therapies. For more information on this animal component-free suspension Pro10™ cell line, access the full PDF detailing its capabilities, which can help reduce process development time and costs.
In a thrilling BMX racing competition in Rock Hill, South Carolina, 33-year-old Alise Willoughby claimed…
Israeli Prime Minister Benjamin Netanyahu and top Hamas leaders are facing arrest warrants from the…
In the wake of new European rules on digital services, the European consumer organization BEUC…
Cher recently attended the premiere of the documentary “Bob Mackie: Naked Illusion” in Los Angeles,…
Amkor Technology, Inc., a leading provider of semiconductor packaging and test services, has announced its…
Jenny Guo, MD, presented the findings of a study on the development of a novel…